The Japan Intergroup Trial of Pemetrexed Adjuvant Chemotherapy for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer (JIPANG) study was a phase III trial in which pemetrexed plus cisplatin was compared with vinorelbine plus cisplatin as adjuvant chemotherapy for completed resected stage II/IIIA nonsquamous NSCLC; in the subgroup analysis of patients harboring EGFR mutations, recurrence-free survival and OS tended to be better in patients who received vinorelbine plus cisplatin than among those who received pemetrexed plus cisplatin [18,19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.